COMBINED APPROACH TO BROADLY PROTECTIVE AIDS VACCINES: CORE B

$465,257P51FY2010RRNIH

University Of Washington, Seattle WA

Investigators

Linked publications & trials

Paper 39605643 Paper 38182420 Paper 37995854 Paper 37695892 Paper 37425739 Paper 37098066 Paper 36738735 Paper 35859531 Paper 35759657 Paper 34862189 Paper 34432996 Paper 34424236 Paper 34006588 Paper 33978232 Paper 33914754 Paper 33479371 Paper 32580663 Paper 31567096 Paper 31405926 Paper 30995136 Paper 30948478 Paper 30699004 Paper 30570484 Paper 30367140 Paper 29899029 Paper 29677324 Paper 29607423 Paper 29566355 Paper 29386511 Paper 29358369 Paper 29305531 Paper 28760867 Paper 28743725 Paper 28450831 Paper 28418297 Paper 28343228 Paper 28159911 Paper 28093479 Paper 27852699 Paper 27820875 Paper 27379234 Paper 27314177 Paper 27194333 Paper 27148554 Paper 27148525 Paper 27069950 Paper 26972791 Paper 26715195 Paper 26571270 Paper 26505868 Paper 26455307 Paper 26438271 Paper 26417083 Paper 26284599 Paper 26086366 Paper 26038465 Paper 26038402 Paper 26029716 Paper 25985411 Paper 25922477 Paper 25855693 Paper 25765047 Paper 25690930 Paper 25661183 Paper 25652917 Paper 25649764 Paper 25637856 Paper 25515075 Paper 25461538 Paper 25445192 Paper 25402233 Paper 25392405 Paper 25355068 Paper 25315244 Paper 25280789 Paper 25253473 Paper 25245586 Paper 25123306 Paper 25102089 Paper 25057148 Paper 25036018 Paper 25032212 Paper 24948811 Paper 24862987 Paper 24803409 Paper 24752373 Paper 24695169 Paper 24616688 Paper 24586139 Paper 24571509 Paper 24567658 Paper 24524450 Paper 24512123 Paper 24478158 Paper 24338748 Paper 24317220 Paper 24174440 Paper 24129645 Paper 24109214 Paper 24107405

Abstract

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This is a part of a study done in coordination with the CaNPRC to compare the in vivo infectivity and pathogenicity of a standard stock of SHIV-SF162 P4 developed for the evaluation of vaccine efficacy in macaque models. In this study, we determined the infectivity of SHIV-SF162 P4 in pig-tailed macaques after intravenous inoculation.

View original record on NIH RePORTER →